GEN Exclusives

More »

GEN News Highlights

More »
Jan 16, 2012

Astex Transfers Anticancer Epigenetics Collaboration to Partner GSK

  • Astex Pharmaceuticals has passed all assets relating to its Climb™ anticancer epigenetics collaboration to GlaxoSmithKline (GSK), its existing partner in the project. The collaboration was initiated between SuperGen and GlaxoSmithKline in 2009, but following last year’s acquisition of Astex Therapeutics by SuperGen, the newly named Astex Pharmaceuticals says a strategic pipeline and drug discovery program review has led to the decision to transfer the program to GSK.

    As a result Astex will have no further obligation to carry out any further research work on the program but will continue to be eligible for milestones and royalties under an asset transfer agreement.

    An ongoing R&D partnership and license agreement between the Astex subsidiary, Astex Therapeutics, and GSK, will continue unchanged. This deal was initiated in November 2009 and includes a multitarget drug discovery arrangement. 


Add a comment

  • You must be signed in to perform this action.
    Click here to Login or Register for free.
    You will be taken back to your selected item after Login/Registration.

Related content

Jobs

GEN Jobs powered by HireLifeScience.com connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.
 Searching...

Unable to get Jobs Listings.

More »

GEN Poll

More » Poll Results »

Lab-Grown Vaginas

Which body part do you think will be successfully engineered in the lab next?